# EDGAR Filing Document

**Accession Number:** 0001349929
**File Stem:** 0001493152-23-008789
**Filing Date:** 2023-3
**Character Count:** 9783
**Document Hash:** 7ea97a2b8720e521ecf45fa12b7480fa
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-008789.hdr.sgml**: 20230324

**ACCESSION NUMBER**: 0001493152-23-008789

**CONFORMED SUBMISSION TYPE**: S-8 POS

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230324

**DATE AS OF CHANGE**: 20230324

**EFFECTIVENESS DATE**: 20230324

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vyant Bio, Inc.
- **CENTRAL INDEX KEY:** 0001349929
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **IRS NUMBER:** 043462475
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8 POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-191520
- **FILM NUMBER:** 23757729

**BUSINESS ADDRESS:**
- **STREET 1:** 2370 STATE ROUTE 70 WEST
- **STREET 2:** SUITE 310
- **CITY:** CHERRY HILL,
- **STATE:** NJ
- **ZIP:** 08002
- **BUSINESS PHONE:** 201.528.9200

**MAIL ADDRESS:**
- **STREET 1:** 2370 STATE ROUTE 70 WEST
- **STREET 2:** SUITE 310
- **CITY:** CHERRY HILL,
- **STATE:** NJ
- **ZIP:** 08002

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CANCER GENETICS, INC
- **DATE OF NAME CHANGE:** 20111216

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CANCER GENETICS INC
- **DATE OF NAME CHANGE:** 20060117

**As filed with the Securities and Exchange Commission on March 24, 2023**

**Registration No. 333- 191520**

**Registration No. 333- 191521**

**Registration No. 333- 196198**

**Registration No. 333- 205903**

**Registration No. 333- 214599**

**Registration No. 333- 256225**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333- 191520**

**Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333- 191521**

**Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333- 196198**

**Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333- 205903**

**Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333- 214599**

**Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333- 256225**

***UNDER THE SECURITIES ACT OF 1933***

 ****

**Vyant Bio, Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| **Delaware** | **04-3462475** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(IRS Employer**<br> **Identification No.)** |

---

**2 Executive Campus**

**2370 State Route 70, Suite 310**

**Cherry Hill, NJ 08002**

**(Address of Principal Executive Offices, including Zip Code)**

**Vyant Bio, Inc. 2021 Equity Incentive Plan**

**StemoniX, Inc. 2015 Stock Option Plan**

**Cancer Genetics, Inc. Amended and Restated 2011 Equity Incentive Plan**

**Cancer Genetics, Inc. Amended and Restated 2008 Stock Option Plan**

**(Full titles of the plans)**

**Andrew D. C. LaFrence**

**2 Executive Campus**

**2370 State Route 70, Suite 310**

**Cherry Hill, NJ 08002**

**(Name and address of agent for service)**

 ****

**(201) 479-1357**

**(Telephone number, including area code, of agent for service)**

 ****

***With copies to:***

**Alan Wovsaniker**

**Lowenstein Sandler LLP**

**One Lowenstein Drive**

**Roseland, New Jersey 07068**

**Tel: 973-597-2500**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**DEREGISTRATION OF SECURITIES**

These post-effective amendments (the "Post-Effective Amendments") are being filed by Vyant Bio, Inc., a Delaware corporation (the "Company"), to remove from registration all shares of the Company's common stock, par value $0.0001 per share ("Common Stock") and any and all other securities of the Company remaining unissued and unsold under the following Registration Statements on Form S-8 (the "Registration Statements") filed by the Company with the Securities and Exchange Commission (the "SEC"):

● Registration Statement No. 333-256225, filed on May 18, 2021, pertaining to the registration of an aggregate of 5,931,780 shares of Common Stock, consisting of: (i) 4,500,000 reserved for issuance pursuant to the Vyant Bio, Inc. 2021 Equity Incentive Plan (the "2021 Plan"), (ii) 891,780 shares of Common Stock pursuant to stock option awards outstanding under the StemoniX, Inc. 2015 Stock Option Plan (the "2015 Plan" and, together with the 2021 Plan, the "Plans"), and any additional securities as may become issuable pursuant to the adjustment provisions of the Plans;

● Registration Statement No. 333-214599, filed on November 14, 2016, pertaining to the registration of an aggregate of 500,000 shares of Common Stock to be issued under the Cancer Genetics, Inc. Amended and Restated 2011 Equity Incentive Plan, and an indeterminable number of shares of Common Stock issuable under such plan, as adjusted as a result of stock splits, stock dividends and anti-dilution provisions;

● Registration Statement No. 333-205903, filed on July 28, 2015, pertaining to the registration of an aggregate of 650,000 shares of Common Stock to be issued pursuant to the Cancer Genetics, Inc. Amended and Restated 2011 Equity Incentive Plan, and an indeterminable number of shares of Common Stock issuable under such plan, as adjusted as a result of stock splits, stock dividends and anti-dilution provisions;

● Registration Statement No. 333-196198, filed on May 23, 2014, pertaining to the registration of an aggregate of 1,650,000 shares of Common Stock to be issued pursuant to the Cancer Genetics, Inc. Amended and Restated 2011 Equity Incentive Plan, and an indeterminable number of shares of Common Stock issuable under such plan, as adjusted as a result of stock splits, stock dividends and antidilution provisions;

● Registration Statement No. 333-191521, filed on October 1, 2013, pertaining to the registration of an aggregate of 350,000 shares of Common Stock to be issued pursuant to the Cancer Genetics, Inc. Amended and Restated 2011 Equity Incentive Plan, and an indeterminable number of shares of Common Stock issuable under such plan, as adjusted as a result of stock splits, stock dividends and antidilution provisions; and

● Registration Statement No. 333-191520, filed on October 1, 2013, pertaining to the registration of an aggregate of 550,000 shares of Common Stock to be issued pursuant to the Cancer Genetics, Inc. Amended and Restated 2008 Stock Option Plan, and an indeterminable number of shares of Common Stock issuable under such plan, as adjusted as a result of stock splits, stock dividends and antidilution provisions.

For ease of reference, all share numbers above are as stated in the Registration Statements, without giving pro forma effect to any adjustments, as applicable, for subsequent events such as stock splits occurring after the original filing dates of the respective Registration Statements.

In accordance with undertakings made by the Company in each the Registration Statements to remove from registration, by means of a post-effective amendment, any and all securities of the Company that were registered for issuance that remain unsold at the termination of the offerings, the Company hereby removes from registration any and all securities of the Company registered but unsold under each of the Registration Statements. As a result of this deregistration, no securities remain registered for sale pursuant to the Registration Statements.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cherry Hill, New Jersey, on March 24, 2023.

---

| | |
|:---|:---|
| **VYANT BIO, INC.** | **VYANT BIO, INC.** |
| By: | */s/ Andrew D. C. LaFrence* |
| Name: | Andrew D. C. LaFrence |
| Title: | President, Chief Executive Officer and Chief Financial Officer |

---

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ Andrew D. C. LaFrence*<br> Andrew D. C. LaFrence | President, Chief Executive Officer and Chief Financial Officer<br> (*Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer*) | March 24, 2023 |
| */s/ John Fletcher*<br> John Fletcher | Chairman of the Board of Directors | March 24, 2023 |
| */s/ Paul Hansen*<br> Paul Hansen | Director | March 24, 2023 |
| */s/ Geoffrey Harris*<br> Geoffrey Harris | Director | March 24, 2023 |
| */s/ Joanna Horobin*<br> Joanna Horobin | Director | March 24, 2023 |
| */s/ Howard McLeod*<br> Howard McLeod | Director | March 24, 2023 |
| */s/ John A. Roberts*<br> John A. Roberts | Director | March 24, 2023 |
| */s/ Ping Yeh*<br> Ping Yeh | Director | March 24, 2023 |

---